Literature DB >> 317204

Influence of moxaprindine treatment on ventricular arrhythmias occurring during maximal exercise stress testing.

H Kesteloot, F van de Werf, B Marchandise, R Sluyts.   

Abstract

Moxaprindine, a new anti-arrhythmic drug, with characteristics similar to aprindine, has been demonstrated to be highly effective in suppressing ventricular arrhythmias occurring before, during and after maximal exercise stress testing. This effect was obtained both in subjects with clinically normal hearts and in a limited number of patients with ischemic heart disease. These findings demonstrate the efficacy and safety of anti-arrhythmic treatment by drugs prolonging ventricular depolarization for ventricular arrhythmias occurring during exercise.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 317204

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  2 in total

Review 1.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

2.  Moxaprindine in the acute treatment of ventricular arrhythmias in patients with cardiovascular disease.

Authors:  J Staessen; H Kesteloot
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.